Copy number alterationカウントは卵巣悪性腫瘍において進行期分類と相関する
演題番号 : WS1-4
Precision medicine based on cancer genomics is being applied in clinical practice. Here we investigated if copy number alteration (CNA) count of gene-panel testing could be a biomarker of malignant ovarian tumors.
Targeted amplicon exome sequencing for 160 cancer-related genes (PleSSision-160) was performed on 88 malignant ovarian tumors (high-grade serous carcinoma (HGSC), 27; endometrioid carcinoma (EC), 15; clear cell carcinoma (CCC), 30; mucinous carcinoma (MC), 6; undifferentiated carcinoma (UC), 4; others, 6 (immature teratoma, 1; carcinosarcoma, 3; squamous cell carcinoma, 1; mixed, 1)) who underwent surgery from January 2012 until September 2017.
The median age was 55 (range: 28-86), clinical stages were I: 41, II: 6, III: 32, IV: 9 and the tumors with recurrence were 30 cases (34.1%). The median PFS and median overall survival (OS) were 1172 days (range: 35-2695) and 1396.5 days (range: 111-2695), respectively. The median CNA count was as follows: HGSC, 53 (range: 6-93); EC, 18 (1-55); CCC, 24 (5-74); MC, 24.5 (11-108); UC, 24.5 (7-42); and others, 36 (10-58). CNA count was significantly higher in HGSC (p<0.005) than in other epithelial ovarian cancers. High CNA count was associated with advanced stage (p<0.001) and worse survival (PFS: HR 0.28, p<0.001; OS: HR 0.30, p<0.05) in all malignant ovarian tumors. CNA count was significantly related with clinical stages (p<0.001, chi-square test). Multivariate analysis including clinical stage, CNA count and patient age showed clinical stage was significantly associated with PFS (p<0.01, Cox-regression model).
High CNA count is associated with advanced clinical stage in malignant ovarian tumors.